DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. - Wikidata - wikimedia - TriplyDB

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

http://www.wikidata.org/entity/Q35031411

about

Clinical management of localized colon cancer with capecitabine Implications of mismatch repair-deficient status on management of early stage colorectal cancer Treatment Individualization in Colorectal Cancer Treatment of colorectal cancer in the elderly Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study Dissecting microsatellite instability in colorectal cancer: one size does not fit all miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Prognostic and predictive significance of MSI in stages II/III colon cancer.Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).Tumor location as a novel high risk parameter for stage II colorectal cancers.Current status of gene expression profiling to assist decision making in stage II colon cancer Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.Is there a prognostic value of tumor location among Chinese patients with colorectal cancer?Immune cells: plastic players along colorectal cancer progression Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803 Genetic predisposition to colorectal cancer: where we stand and future perspectives Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis.Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps.High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study.Retinal mitochondrial DNA mismatch repair in the development of diabetic retinopathy, and its continued progression after termination of hyperglycemia.The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes Does young age influence the prognosis of colorectal cancer: a population-based analysis.Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer

P2860

Q24611758-12DAD5B6-A2C1-4ECA-B214-26F729295F02 Q26772272-A7A4A45F-8FA3-4530-9478-0681DBEE57BB Q26776215-9142112B-0A49-4D78-8A02-40C6ABD3D9B1 Q26781457-27286BCD-B42B-4BD2-979A-EEF24CB7A0DD Q27693248-280BD69A-A2F6-4A92-804A-D92E7E1FA8A1 Q28069924-4505D808-CDED-482C-8CFD-FE5B1909193C Q28070038-BFB4AC33-C2D1-4874-8DD3-2A9F5787C6A7 Q28249648-EB1BA7D8-C4AA-45D7-92AD-EFCFA9746D31 Q28647615-1BC292DA-B96E-492C-B4AA-6ED92196D9E7 Q30378082-EAF79C30-40E2-4BEF-BCB2-ABDA2AF01E83 Q31012680-C7ECC988-C89E-45BE-B28E-694778902630 Q33438899-B7FA36C8-ADEF-4EAA-8F65-2A7250B5E4FF Q33615076-F1C9CBE5-6FDE-4EA6-9B9F-2817F7A5D853 Q33682949-E6343424-345A-4D3A-B9D0-7C0436FD4389 Q33722794-7D6303C8-BE6B-4CED-9BF0-B9B2D0D7D5A1 Q33726141-1396C728-8896-497F-B849-33C173514F49 Q33727842-42F874EB-6AD6-45B5-BE6F-BF4CB1837DD4 Q33735239-A2287FB0-F61E-42D2-84F6-AC197686B188 Q33765195-89FF7334-7A5A-4BEA-8170-492AC98E8958 Q33813216-4087EAAA-F07E-4B94-88A2-B6444574EB69 Q33828917-F87A1171-1694-402C-BF94-F5203E3A0DDD Q33829763-8CC76282-E735-4F4B-96DA-21D4D68A029D Q33848817-0D85F07D-035C-45E4-B430-69650E23A6C4 Q33888917-767E3620-0076-43AD-88EF-EA6DB96979C1 Q33985586-C44CEC81-9DA0-4E9B-ABC5-3A0AE6FF1971 Q34004105-CEC6B035-B70F-48F8-B8AC-6BFAFD5AA9F0 Q34008801-318A8DA8-C0C3-496E-A701-58DF70EC883B Q34169734-F2B53EE5-EE96-4670-ACBF-94EA789C6416 Q34276740-100048FD-9A03-4D77-9585-B1DF977189D2 Q34293192-B7BE8687-53A5-4A01-8DE7-E454C4FFFD84 Q34396531-4D6FEC12-E768-4703-8424-DE1647F9164E Q34433611-C6CAC696-3BA1-400C-9B78-9CFE9DABB15F Q34441849-0C0789E6-2A7E-4BD1-B6BF-AB62615358F2 Q34472453-6853586B-BDF6-437A-BCC6-8D13A47C4131 Q34532108-56394011-ADD7-4438-B77D-144824066F38 Q34656360-49F03347-3A9A-45A2-9057-07E84360354A Q34665492-95E6652C-FD51-4A26-9182-EFB987A61890 Q34695185-CF67B775-26F7-4E55-BB4A-60664390A99B Q34982575-284CEA62-62C7-443C-97FF-8A23BB398E9C Q35012132-DF463188-FCD9-4A2B-A422-044AD60EB146

P2860

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

http://www.wikidata.org/entity/Q35031411

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@ast

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@en

type

label

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@ast

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@en

prefLabel

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@ast

DNA mismatch repair status and ...... uracil-based adjuvant therapy.

@en

P1433

Q35031411-89E9FBC0-9617-48F8-A874-FFF54399E903

P1476

Q35031411-0BF1F8C5-D50C-4E92-BD09-D7C91DA2163E

P2093

Q35031411-1354FD12-95CD-481E-96D9-658B51F61BC7

Q35031411-228B34AE-BD0E-409C-955A-2027CA58E0FE

Q35031411-6054C9B1-B730-4BCF-95AF-C0EBDC17896F

Q35031411-71895502-FC17-4DE8-90D2-C98301E823B5

Q35031411-75345C06-414B-4936-9B8B-34B67C2C58CA

Q35031411-7A31B172-3B82-4160-8550-0C48CB772237

Q35031411-88958F69-BAC6-4CA6-ACCB-AB2B4691DE1A

Q35031411-EC6F4CC6-40D3-47D2-A419-C89704E22D14

P2860

Q35031411-0A305286-8BEF-42B8-9449-169071CD1F29

Q35031411-215DCE29-5445-4865-A3BF-E864A127D44C

Q35031411-2BE9DFDA-0AF5-4B02-A79D-F57A59815D5C

Q35031411-2FFDD040-CB21-4776-A480-A42857FFBEAE

Q35031411-37B52A87-2F69-47C4-9CDF-FA80B321A38C

Q35031411-38C6F921-876E-424A-A515-6CCF33A17626

Q35031411-42067F40-9080-4F49-AAF3-2A2ECFACFF1E

Q35031411-43EF7DCA-8028-422D-9F3F-5E44FFD01A19

Q35031411-465AA9D5-5E84-4634-AF1B-F6F6F8E8D1A9

Q35031411-4E8E3F62-8AF5-435D-817B-BBBC6A6237E2

P304

Q35031411-46EE5D63-0B83-43A6-9135-6DEE82E6F2F8

P31

Q35031411-C4A614AB-63E8-4C90-8464-9D667B3C67FB

P356

Q35031411-36476B68-0E50-45EC-88DC-D40D6FCC95F1

P407

Q35031411-6EF537E7-618B-4AA5-9EEC-3D19A6DB36B6

P433

Q35031411-2A1B806C-B521-4019-9604-3ED38308C847

P478

Q35031411-44C704A6-6238-4E98-B745-239070D0D6D5

P50

Q35031411-97122776-8BEA-42D5-A82E-D646C35AB13B

Q35031411-C14A979E-5873-45C7-B8B7-9D0DE823D504

Q35031411-DCCC6E5B-E935-48BD-AFBF-D016AF31EBB4

Q35031411-E96BD9D1-D443-4656-90DF-3E88D8B61343

P577

Q35031411-C4678604-8D8C-4DC9-8C6A-7810F0855166

P5875

Q35031411-FB8892D9-88DA-41AA-A395-35A39C70A96F

P698

Q35031411-C378440B-AC88-43CF-9FCA-DFFD6FD6DFEC

P932

Q35031411-25C8F81D-259D-420A-A9DD-AB5EAC84EA12

P356

P1433

Journal of the National Cancer Institute

P1476

DNA mismatch repair status and ...... ouracil-based adjuvant therapy

@en

P2093

Carmen Allegra

http://www.w3.org/2001/XMLSchema#string

Frank A Sinicrope

http://www.w3.org/2001/XMLSchema#string

Genevieve Monges

http://www.w3.org/2001/XMLSchema#string

George P Kim

http://www.w3.org/2001/XMLSchema#string

Malcolm J Moore

http://www.w3.org/2001/XMLSchema#string

Nathan R Foster

http://www.w3.org/2001/XMLSchema#string

Stephen N Thibodeau

http://www.w3.org/2001/XMLSchema#string

Steven Gallinger

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

Cancer statistics, 2009

Microsatellite instability in cancer of the proximal colon

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

P304

863-875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR153

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Labianca

Daniel J. Sargent

P577

2011-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51150859

http://www.w3.org/2001/XMLSchema#string

P698

21597022

http://www.w3.org/2001/XMLSchema#string

P932

3110173

http://www.w3.org/2001/XMLSchema#string